T2 Biosystems Announces Participation at Clinical Conferences in February
February 04 2020 - 9:30AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today announced the
Company’s participation in two conferences in February: Society of
Critical Care Medicine’s (SCCM) 48th Critical Care Congress, and
Medlab Middle East 19th Annual Laboratory Management and Medicine
Conference.
“A recent study in The Lancet estimated that 11
million people died with sepsis in 2017 -- accounting for nearly
20% of all deaths worldwide -- more deaths than all forms of cancer
combined,” said John Sperzel, Chief Executive Officer of T2
Biosystems. “We are excited to further demonstrate how our
technology is helping to improve clinical outcomes and make a
meaningful difference in the lives of patients suspected of
sepsis.”
At the Medlab Middle East congress in Dubai,
held February 3-6, 2020, Professor Pavel Drevinek, M.D., Ph.D. from
Motol University Hospital in the Czech Republic will present,
“Using T2MR Technology for rapid detection of ESKAPE Pathogens
directly from whole blood.” The presentation will highlight the
real-world, positive impact that T2 Biosystems’ rapid diagnostics
that detect sepsis-causing pathogens can have on patients and
clinicians.
During the SCCM’s Congress, held in Orlando,
Florida, on February 16-19, 2020, the Company, including T2
Biosystems’ Vice President of Medical Affairs, Sandy Estrada,
Pharm. D., will highlight the capabilities of its T2Bacteria® and
T2Candida® panels. These panels are the only FDA cleared diagnostic
tools that can detect sepsis-causing pathogens in the bloodstream
directly from whole blood, providing results in three to five hours
instead of days, as is seen with current blood culture-based
methods. As a result, patients can receive targeted treatment
sooner, and hospitals can better manage costs associated with
identifying and treating sepsis, including antimicrobial costs.
Attendees can learn more about the Company’s
innovations, as well as their clinical and economic benefits, at
SCCM at Booth #1123.
About T2 BiosystemsT2
Biosystems, a leader in the development and commercialization of
innovative medical diagnostic products for critical unmet needs in
health care, is dedicated to improving patient care and reducing
the cost of care by helping clinicians effectively treat patients
faster than ever before. T2 Biosystems’ products include the T2Dx®
Instrument, the T2Candida® Panel, the T2Bacteria® Panel, and the
T2ResistanceTM Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including products for the detection of
additional species and antibiotic resistance markers of sepsis
pathogens, and tests for Lyme disease.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including, without limitation, statements regarding
additional patients, timing of testing patients, anticipated
product benefits, strategic priorities, product expansion or
opportunities, growth expectations or targets, timing of FDA
filings or clearances and anticipated operating expenses, as well
as statements that include the words “expect,” “intend,” “plan”,
“believe”, “project”, “forecast”, “estimate,” “may,” “should,”
“anticipate,” and similar statements of a future or forward looking
nature. These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments,
contracts or products; (b) successfully execute strategic
priorities; (c) bring products to market; (d) expand product usage
or adoption; (e) obtain customer testimonials; (f) accurately
predict growth assumptions; (g) realize anticipated revenues; (h)
incur expected levels of operating expenses; or (i) increase the
number of high-risk patients at customer facilities; (ii) failure
of early data to predict eventual outcomes; (iii) failure to
make or obtain anticipated FDA filings or clearances within
expected time frames or at all; or (iv) the factors discussed under
Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K
for the year ended December 31, 2018, filed with the U.S.
Securities and Exchange Commission, or SEC, on March 14, 2019, and
other filings the company makes with the SEC from time to
time. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While the company may elect to
update such forward-looking statements at some point in the future,
unless required by law, it disclaims any obligation to do so, even
if subsequent events cause its views to change. Thus, no one should
assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements
should not be relied upon as representing the company's views as of
any date subsequent to the date of this press release.
Media Contact: Gina Kent, Vault
Communications gkent@vaultcommunications.com
610-455-2763
Investor Contact: Zack Kubow, W2O Group
zkubow@w2ogroup.com 415-658-6436
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024